Avobis Bio Reveals New Insights from STOMP2 Study at ECCO Congress Avobis Bio presented updated results from the STOMP2 clinical trial at the ECCO Congress, showing promising outcomes for Crohn's disease treatments.

Avobis Bio Reveals New Insights from STOMP2 Study at ECCO Congress #USA #Newark #Avobis_Bio #AVB-114 #STOMP2

Avobis Bio Reveals Promising Results for AVB-114 in STOMP2 Clinical Trial at ACG Annual Meeting Avobis Bio has announced encouraging primary analysis results from the STOMP2 clinical trial, showcasing the efficacy of their investigational therapy AVB-114 for Crohn's disease.

Avobis Bio Reveals Promising Results for AVB-114 in STOMP2 Clinical Trial at ACG Annual Meeting #USA #Newark #Crohn's_Disease #Avobis_Bio #AVB-114

Avobis Bio's AVB-114 Secures RMAT Designation from FDA for Crohn's Fistulas Avobis Bio has announced that the FDA granted RMAT designation for AVB-114, its innovative therapy for Crohn's perianal fistulas, accelerating trials.

Avobis Bio's AVB-114 Secures RMAT Designation from FDA for Crohn's Fistulas #United_States #Newark #Crohn's_Disease #Avobis_Bio #AVB-114

Avobis Bio Achieves Key Milestone in Clinical Development of AVB-114 for Crohn's Disease Avobis Bio announces successful primary analysis of STOMP-II clinical trial, requesting RMAT designation for AVB-114 targeted at Crohn's disease.

Avobis Bio Achieves Key Milestone in Clinical Development of AVB-114 for Crohn's Disease #United_States #Newark #Inflammatory_Bowel_Disease #Avobis_Bio #AVB-114

Avobis Bio's AVB-114 Cell Therapy Receives Fast Track Designation from FDA Avobis Bio has gained FDA Fast Track designation for AVB-114, an innovative implantable cell therapy for Crohn's perianal fistulas, promising significant advancements in treatment.

Avobis Bio's AVB-114 Cell Therapy Receives Fast Track Designation from FDA #United_States #Newark #FDA_Fast_Track #Avobis_Bio #AVB-114